Simple Summary The prognosis for metastatic prostate cancer patients remains poor.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a …

The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …

Continuous progress in the diagnostics and treatment of neuroendocrine neoplasms
(NENs), the emerging results of new clinical trials, and the new guidelines issued by medical …

A growing body of literature reports on the combined use of peptide receptor radionuclide
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …

Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among
all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs …

Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …

A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor
radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine …

Simple Summary Functional imaging methods and, in particular, positron emission
tomography (PET) using several radiopharmaceuticals may play a pivotal role in patients …

Common to neuroendocrine neoplasms of the pancreas is their expression of
synaptophysin, chromogranin A, and/or INSM1. They differ, however, in their histological …